S952
Clinical - Non-malignant & functional radiotherapy
ESTRO 2026
vestibular symptoms, including dizziness and imbalance, were reported in some patients. Importantly, no severe (grade ≥ III) toxicity occurred. Conclusion: CyberKnife SRS is an effective and safe treatment for vestibular schwannoma, providing high tumor control, excellent hearing preservation, and minimal side effects. Each apparent tumor progression should be carefully evaluated to determine whether it represents true progression, pseudoprogression, or variability arising from interobserver differences in contouring. Standardized imaging protocols and consistent volumetric measurements are essential for correct
for cerebral arteriovenous malformations : Evaluation of long-term outcomes in a single institute cohort. Strahlenther Onkol. 2025.[2] Greve T, Ehret F, Hofmann T, Thorsteinsdottir J, Dorn F, Š vigelj V, et al. Magnetic Resonance Imaging-Based Robotic Radiosurgery of Arteriovenous Malformations. Front Oncol. 2020;10:608750. Keywords: Arteriovenous malformation, hypofractionated SRS Digital Poster 3673 Cyberknife Stereotactic Radiosurgery For Vestibular Schwannoma: 9-Year Single-Centre Experience Sandra Ledina 1 , Maris Mezeckis 1 , Vladyslav Buryk 1 , Karina Anete Mazjane 2 , Elizabete Stankevica 2 , Indra Surkova 1 , Galina Boka 1 1 Radiosurgery Centre Sigulda, Sigulda Hospital, Sigulda, Latvia. 2 Faculty of Medicine and Life science, University of Latvia, Riga, Latvia Purpose/Objective: Vestibular schwannomas are benign tumors of the eighth cranial nerve that frequently lead to progressive hearing loss and balance disturbances. CyberKnife stereotactic radiosurgery (SRS) offers a minimally invasive treatment option, aiming to control tumor growth while preserving neurological function. This study presents a retrospective, single-center experience with vestibular schwannoma, evaluating tumor control, treatment-related toxicity, and hearing preservation. Material/Methods: We retrospectively analyzed 85 patients with vestibular schwannoma treated with CyberKnife SRS between 2015 and 2024. The median age was 55 years (range 15–85), with 57% female. Prior microsurgery had been performed in 17% of patients. Treatment regimens included single-fraction SRS in 68% of cases, three-fraction in 26%, and five-fraction in 6%, with a median dose 12Gy (12Gy-14Gy); 18Gy (18Gy-25.5Gy); 25Gy (25Gy-27.5Gy). Follow-up MRI was performed annually for the first three years and every two years thereafter, with a median follow-up of 49.7 months, IQR [37.1-69.5]. Tumor volumes were assessed using the Accuray planning system and categorized as shrinkage ( ≥ 20% reduction), stable disease ( − 20% to +20% change), or progression ( ≥ 20% increase). Clinical symptoms and hearing outcomes were systematically recorded. Results: Volumetric analysis demonstrated tumor shrinkage in 46% of patients and stable disease in 24%. Among 80 patients with residual pre-treatment hearing, 76 (95%) retained functional hearing after SRS. Transient
interpretation of follow-up imaging and for comparison of the results across studies. References:
Brun L, et al. “The Recent Management of Vestibular Schwannoma and Radiotherapy: A Review of the Last Ten Years.” J. Clin. Med. 2024;13(6):1611.Tavares M P, Bahmad Jr F. “Hearing Function after CyberKnife for Vestibular Schwannoma: A Systematic Review.” Int. Arch. Otorhinolaryngol. 2024. Keywords: vestibulocochlear, schwannoma, radiosurgery Digital Poster 3987 Radiation Therapy for Benign Conditions: Clinicians’ Experiences and Future Intentions in an ESTRO Membership Survey Sarah Barrett 1,2 , Darragh P Browne 3 , Yin Yin Sheng 1 , Charles Gilham 3 , Osama Salib 3 , Gerard G Hanna 1,3 1 Discipline of Radiation Therapy, Trinity College Dublin, Dublin, Ireland. 2 Trinity St. James’s Cancer Institute, Trinity College Dublin, Dublin, Ireland. 3 St. Luke's Radiation Oncology Network, St. Luke’s Hospital Rathgar, Dublin, Ireland Purpose/Objective: The clinical application of radiotherapy (RT) for benign conditions is expanding [1] yet comprehensive data on its current utilisation remains limited and dated [2]. This study sought to capture contemporary practice patterns among members of the European Society for Radiotherapy and Oncology (ESTRO) and to explore future intentions regarding the use of RT in benign disease management. Material/Methods: An anonymous, web-based survey comprising five sections and 24 questions was disseminated to individual Oncologists (hereafter referred to as "respondents"). Distribution was conducted via ESTRO communication channels targeting all clinician members (n=5,127). The survey collected data on respondent demographics, current RT practices for benign conditions, perceived barriers to
Made with FlippingBook - Share PDF online